Video
Author(s):
Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.
First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
Pitavastatin Offers Therapeutic Potential in Cancers Arising From Chronic Inflammation
Revisit Every OncLive On Air Episode From May 2024
Dr Ramalingam on Osimertinib Post-Chemoradiotherapy in Unresectable EGFR-Mutated NSCLC
Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer
Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases